Of 300 consecutive patients undergoing primary operation for mitral valve replacement combined with coronary bypass grafting, 22 (7.3%) died in-hospital. Multivariate testing of preoperative and operative descriptors identified radiographic cardiac enlargement, preoperative paced rhythm or atrial fibrillation, 70% or more left main coronary obstruction, and serum bilirubin of more than 2 mg% as factors associated with an increase in in-hospital mortality. Follow-up of the 278 hospital survivors (mean interval 48 months, range 2 to 165 months) documented survival of 85%, 66%, and 31% and an event-free survival of 65%, 46%, and 21 % at 2, 5, and 10 postoperative years, respectively. Cox proportional-hazard regression models of late risk implicated in-hospital ventricular arrhythmias, left ventricular dysfunction, and rheumatic or ischemic causes of mitral valve disease in decreasing long-term survival. In addition, patients with bioprostheses without warfarin anticoagulation had better survival and event-free survival than those with bioprostheses taking warfarin and those with mechanical prostheses with or without warfarin.
PATIENTS with a combination of coronary atherosclerosis and mitral valve disease represent a continuing challenge to cardiologists and surgeons. Coronary bypass grafting is an effective operation for patients with isolated coronary atherosclerosis, consistently relieving angina and, for some subgroups of patients, also prolonging survival.1-' Mitral valve replacement improves the symptoms of most patients with hemodynamically significant mitral valve dysfunction, is lifesaving for patients with acute, severe mitral insufficiency, and may improve survival for patients with chronic mitral valve dysfunction as well.4 5 However, the risks of operations combining mitral valve replacement with coronary bypass grafting have been high; reported rates of perioperative death range from 14% to 24%.>°Furthermore, the few data available regarding long-term survival document substantial late attrition of operative survivors. 8 Analysis of the causes of treatment failure is difficult because patients with mitral valve and coronary artery disease are a heterogenous group in terms of the causes of their mitral valve dysfunction, the extent of coronary atherosclerosis, left ventricular function, hemodynamic status at operation, and many other patient-related factors. Intraoperative management, prosthesis selection, and anticoagulation strategies add further variables. To document the results of operation and to identify the factors influencing early and late risk, the first 300 patients undergoing primary operation for mitral valve replacement combined with coronary artery bypass grafting were reviewed.
Methods
Methods of patient identification, data collection, and patient follow-up have been previously described. '1 The study group comprised the first 300 consecutive patients undergoing a primary cardiac operation limited to mitral valve replacement combined with coronary bypass grafting. These criteria excluded patients undergoing cardiac reoperation, mitral valve reconstruction, or concomitant aneurysmectomy, aortic valve surgery, or carotid operation. Both elective and emergency cases are included. All patients underwent operation between January 1, 1970 and August 1, 1983. Preoperative data. The preoperative clinical variables examined are listed in table 1. All patients underwent preoperative left heart catheterization and coronary arteriography; 199 (66.3%) of the studies were performed at the Cleveland Clinic Foundation. Table 2 lists the angiographic and hemodynamic variables examined. Patients were grouped into categories of single-, double-, and triplevessel disease on the basis of the number of major vessels with obstructions of 70% or more. Detailed criteria for the definition of the extent of coronary atherosclerosis and for evaluation of left ventricular contraction via analysis of the right anterior oblique left ventriculogram have been described." A preoper-1180 ative left ventriculogram was not available for one patient. Patients with mitral stenosis were classified as having "mixed" lesions if 1/4 + or greater mitral regurgitation was also present. Designation of tricuspid valve insufficiency was based on clinical findings, whereas the aortic valve was considered abnormal if a gradient of 20 mm Hg or more or any sign of aortic regurgitation was present at catheterization. Valve pathology. Patients were grouped as to the cause of mitral valve dysfunction by review of clinical, operative, and histologic findings ( AExcluding patients with left main coronary stenosis .70%. matic, degenerative, infective, and congenital valve disease. Criteria for categorization were as follows: Ischemic: Operative finding of a ruptured papillary muscle (13 patients), or operative or histologic documentation of a nonruptured but infarcted papillary muscle (21 patients), or previous myocardial infarction and mitral valve insufficiency without clear documentation of papillary muscle necrosis or rupture and without significant rheumatic or degenerative valve pathology (13 patients).
Degenerative: Pure mitral insufficiency with histologic evidence of myxoid change.
Rheumatic: All cases of stenosis with or without insufficiency were considered rheumatic. Cases of pure insufficiency with thickened leaflets, calcified leaflets, chordeal shortening, or chordeal thickening were considered rheumatic.
Endocarditis: Culture-positive endocarditis (two patients) or healed endocarditis with leaflet perforation (one patient).
Congenital: A single case of long-standing mitral insufficiency with a cleft leaflet was considered congenital.
Operative data. solution) was first employed in 1976 and is now used in all patients. When cardioplegia is used, systemic hypothermia is induced, the aorta is cross-clamped, cardioplegic solution is injected into the aortic root, and valve replacement along with all distal anastomoses are accomplished under a single period of aortic cross-clamping. Proximal anastomoses are then constructed with the aorta unclamped. Valve selection was based on surgeon preference. Mechanical prostheses were employed in 138 cases (46%) and bioprostheses were used in 162 (54%). Specific types of mechanical prostheses used were as follows: Bjork-Shiley, 21 (7%); Lillehei-Kaster, seven (2.3%); St. Jude, four (1.3%); Starr-Edwards (6120), 80 (26.7%); other Starr-Edwards, three (1%); and Cutter-Smeloff, 23 (7.7%). Bioprostheses used were Hancock porcine, 83 (27.7%); Carpentier-Edwards porcine, 78 (26%); and Ionescu-Shiley, one (0.3%). Bioprostheses were first used in 1975, and since 1979 have been used in the majority of cases. However, the highest percent of patients receiving bioprostheses in any year has been 82%.
Postoperative data. Early death (in-hospital mortality) was defined as death during hospitalization for surgery regardless of duration. Death occurring after discharge from this hospitalization period was considered late death. Postmortem examinations were performed in seven (32%) of the 22 patients who died during the operative hospitalization and in 14 (14%) of 99 patients dying after discharge.
Postoperative electrocardiograms were available for all survivors of surgery, as were at least one postoperative SGOT level for 1 of the first 2 postoperative days. Eighty-three patients were classed as having postoperative ventricular arrhythmias based on the documentation of ventricular fibrillation or tachycardia, multifocal premature ventricular extrasystoles, or multiple unifocal ventricular extrasystoles that required treatment.
Late follow-up. Criteria for classification of late death and late cardiac events have been used previously.11
Patients were separated into two groups, those receiving anticoagulants and those not receiving anticoagulants, based on whether or not they were taking warfarin at follow-up. Patients who had not been taking warfarin for at least 2 weeks before 1182 either death or the occurrence of a morbid event were classed as not receiving anticoagulants. Adequacy of anticoagulation was not assessed and use of platelet-inhibiting drugs was not considered.
Statistical methods. Univariate testing of variables concerning end points not related to time were evaluated with chisquared analyses or Fisher's exact test. Multivariate testing was then done with stepwise multiple logistic regression analysis.'2 The influence of variables concerning the occurrence of timerelated events was examined by univariate analysis with life table methods'3 and the generalized Wilcoxon test. 14 Multivariate analyses were carried out with Cox proportional-hazard regression models. 15 A p value of .05 or less was considered to indicate statistical significance.
Results
In-hospital mortality. There were 22 (7.3%) in-hospital deaths. Three patients died in the operating room of myocardial failure. Four died, after operation, of new myocardial infarction (new Q waves, loss of R waves, or documentation at autopsy), and three patients died after operation of myocardial failure but without documentation of new infarction. Three patients died of respiratory failure, two from strokes, and one each from sepsis, renal failure, aortic rupture, and ruptured abdominal aortic aneurysm. Three patients died of multisystems failure after a complex prolonged postoperative course.
In-hospital morbidity. Of 297 patients who survived surgery, 25 (8.4%) had new Q waves or loss of R waves documented electrocardiographically. Five (20%) of these 25 patients died compared with 14 (5.2%) of the 272 patients without electrocardiographic changes (p = .004). New Q waves were documented in 13 of the 143 patients (9%) operated on with anoxic arrest and 12 (8%) of the 154 given cardioplegia (p = NS).
Intra-aortic balloon pumping was used in 21 patients. The intra-aortic balloon was inserted preoperatively in six patients (one death, 17%), intraoperatively in 11 patients (three deaths, 27%), and postoperatively in four patients (two deaths, 50%). Of 35 patients requiring inotropic support for more than 48 hr, 11 (31%) died.
Sixty-seven patients (22%) experienced noncardiac morbidity. The number of patients and the percentage of the group with each complication were as follows: perioperative bleeding requiring reoperation, 42 (14%); permanent stroke, nine (3%); transient neurologic change, 30 (10%); wound complication, 15 (5%); and renal failure (blood urea nitrogen > 100), 1 1 (4%). Univariate testing of the likelihood of mortality once each complication had occurred showed that all were significantly associated with eventual in-hospital mortality (p < .001 for all). Fifty-nine patients had THERAPY AND PREVENTION-CARDIAC SURGERY noncardiac morbidity and did not experience cardiac morbidity (new Q waves); 12 of these patients (20%) died.
Preoperative variables. Preoperative clinical, catheterization, and pathologic variables and the results of univariate analyses of the influence of those variables on in-hospital mortality are shown in tables 1 to 3. Age (mean age 60.2 + 8.3 years, range 32 to 84) was examined according to decade of life. Body surface area, serum cholesterol, serum triglyceride, blood urea nitrogen, serum bilirubin, and left ventricular end-diastolic pressure had no influence on risk when examined as continuous variables.
Angina was associated with the number of coronary vessels obstructed and valve pathology. Of patients with one-, two-, and three-vessel disease, 53.5%, 75.9%, and 78.5%, respectively, had angina (p < .001). Ten of the 11 patients with left main obstruction of 70% or more had angina. Of patients with ischemic mitral valve disease, five of 47 (10.6%) had no angina preoperatively compared with 42 of 102 (41%) with rheumatic and 45 of 147 (31%) with degenerative valve disease (p = .002).
Division of the group into the first, second, and third cohorts of 100 patients each showed no significant differences among the cohorts with regard to the number of coronary vessels obstructed, valve pathology, or left ventricular function. The most recent cohort contained older patients, however, with 24 patients 70 years or older compared with 14 in the second cohort and two in the first (p < .001).
Preoperative noninvasive variables having a significant univariate influence on in-hospital mortality (table 1) were radiographic cardiothoracic ratio (p < .001), serum bilirubin of more than 2.0 mg% (p = .006), and preoperative rhythm (p = .002).
The number of coronary vessels with 70% or more obstruction did not influence hospital risk, but left main coronary obstruction did (table 2) . Eleven patients had left main stenosis of 70% or more and three of these died (27%) compared with 19 (6%) of 289 patients without stenosis of this degree (p = .01). None of the 11 patients with left main stenoses of from 50% to 69% died.
Valve pathology did not significantly influence operative risk. Examination of operative risk for the subgroups of patients with ischemic valve pathology showed that two of 13 patients with a ruptured papillary muscle, two of 21 with infarcted papillary muscle, and one of 13 with previous myocardial infarction died (p = NS).
The hemodynamic variables of left ventricular end-Vol. 71, No. 6, June 1985 diastolic pressure and pulmonary capillary wedge pressure were influential when extremes of their ranges were tested univariately (table 2) . Two hundred sixty-three patients had a left ventricular end-diastolic pressure of 30 mm Hg or less and 16 died (6%) compared with four (28%) of the 14 patients who had a left ventricular end-diastolic pressure of greater than 30 mm Hg (p = .006). Of 23 patients with a pulmonary capillary wedge pressure of 40 mm Hg or less, 11 died (5%) compared with four (44%) of nine with a pulmonary capillary wedge pressure of greater than 40 mm Hg (p < .001). Because data regarding these variables were not available for some patients, they were not tested in the multivariate model.
Operative variables. In addition to the variables in table 4, total aortic occlusion times were examined separately for cardioplegia and anoxic arrest. In neither method of myocardial protection was aortic occlusion time related to hospital mortality.
Grouping valves into major groups of mechanical prostheses vs bioprostheses or testing individual makes of valves against each other showed these variables had no influence on early mortality.
No operative variables univariately influenced inhospital mortality.
Multivariate analysis: in-hospital mortality. A logistic regression analysis was done including 11 variables in the model. Cardiac enlargement, cardiac rhythm, left main obstruction of 70% or more, and serum bilirubin were included because of significance with univariate testing. Elevated preoperative blood urea nitrogen (>25 mg%), a history of congestive heart failure, age, and preoperative left ventricular function (normal or mild impairment vs moderate or severe impairment) were included because of trends (p < .20) found with univariate testing. Gender, myocardial protection (anoxic arrest versus cardioplegia), and cause of valve dysfunction (ischemic vs degenerative vs rheumatic) were also included. In this multivariate model (table  5) , cardiac enlargement and left main stenosis were associated with increased mortality, sinus rhythm with decreased mortality, and elevated bilirubin with marginally increased mortality.
Late results. Of the 278 patients surviving the operative hospitalization, 99 subsequently died. Survivors were followed for from 2 to 165 months (mean followup 48 months) with survival of 92%, 85%, 66%, and 31 %, at 1, 2, 5, and 10 postoperative years, respectively (figure 1). Eighty-seven (88%) of the late deaths were cardiac; 12 (12%) were judged noncardiac.
The variables in tables 1 through 4 were tested for their influence on late survival. Deaths from any cause 2 ). When the subgroups of patients with ischemic valve disease were compared, survival at 4 postoperative years was 68% for those with papillary muscle infarction, 58% for the group with previous myocardial infarction but no documented papillary muscle pathology, and 100% for those operated on for papillary muscle rupture (p = .08). Postoperative hospital variables tested were new Q waves, stroke, and reoperation for bleeding, none of which were significant, and postoperative ventricular arrhythmias. The presence of postoperative ventricular arrhythmias had a negative influence; the late survival of patients with arrhythmias was inferior (p = .02) to that of patients without arrhythmias. There was no association between the occurrence of postoperative ventricular arrhythmias and preoperative angiographic left ventricular function.
Survival of patients with bioprostheses was superior to that of patients with mechanical prostheses (p = .0 1). Prosthesis type and postoperative anticoagulation with warfarin were examined together by dividing the study group into four subgroups based on the type of prosthesis and whether or not the patient had received anticoagulants. Survival was significantly better for patients with bioprostheses who were not taking anticoagulants than for any other group ( figure 3) .
The relationship between prosthesis-anticoagulation status and preoperative rhythm was examined in detail. Of 169 patients in sinus rhythm, 29 (17%) received bioprostheses and anticoagulants, 57 (34%) bioprostheses without anticoagulants, four (2%) mechanical valves without anticoagulants, and 79 (47%) mechanical valves with anticoagulants. Of 100 patients in atrial fibrillation, 38 (38%) received bioprostheses and anticoagulants, 22 (22%) bioprostheses without anticoagulants, one a mechanical valve without anticoagulants, and 39 (39%) mechanical valves with anticoagulants. Patients with bioprostheses who had atrial fibrillation were more likely (p -.02) to have received anticoagulants than were those in sinus rhythm. However, for patients with sinus rhythm and bioprostheses, survival was not significantly altered by whether or not they were taking anticoagulants (p = .87), whereas patients with atrial fibrillation and bioprostheses who did not take anticoagulants had better survival (p = .06) than those who did. Postoperative rhythm was not assessed. There were no significant differences in patient distribution among the three major prosthesis-anticoagulation groups when tested with regard to age, angiographic left ventricular function, and in-hospital ventricular arrhythmias. Patients with rheumatic mitral dysfunction were slightly more likely to have received a mechanical prosthesis (p = .03).
Multivariate analysis: late survival. Twelve variables were examined with a Cox regression model for influence on late survival. Left ventricular function, valve pathology, postoperative ventricular arrhythmias, and prosthesis-anticoagulation group were included in the model because of significance with univariate testing. Dyspnea (none vs class III or IV), diabetes, duration of preoperative symptoms, and number of vessels with 70% or greater stenoses were included because of trends (p < .20) identified with univariate testing. Preoperative cardiac enlargement and rhythm were included because of their impact on early survival, and age and gender were included because of their known influence in studies of other patient subsets. Results of that analysis (table 6) showed that the prosthesesanticoagulation group to which the patient belonged had the strongest influence on survival. Patients with 64.7% 45.5% 42.8% bioprostheses and who were not taking anticoagulants had survival superior to that in the other groups. The presence of ventricular arrhythmias postoperatively decreased survival as did moderate or severe impairment of left ventricular function and rheumatic valve pathology.
Event-free survival. One hundred ten patients experienced 184 major complications (late cardiac events), and 66 of these patients subsequently died (table 7) . Fifty-seven survivors experienced a single cardiac event. Event-free survival (figure 1) was 74%, 65%, 46%, and 21% at 1, 2, 5, and 10 postoperative years, respectively. Of the 12 cardiac reoperations, nine were related to the mitral prosthesis (mechanical valve dysfunction, four; bioprosthesis failure, three; repair of paravalvular leak, two), one was for tricuspid valve replacement, and two were for repeat bypass grafting. Four patients died at reoperation. Univariate analysis of the same variables that were tested with regard to survival showed that angina, extent of disease, and prostheses-anticoagulation group ( figure 4) double-vessel disease or with duration of symptoms of more than 5 years were at greater risk. Postoperative symptom status. Postoperative NYHA functional class in the 179 late survivors was I, 142 (79%); II, 33 (18%); III, two (1%); IV, 0. No patient was symptomatically worse after surgery. Of the 35 symptomatic patients, 16 had angina and 28 had dyspnea.
Postoperative angiography. Forty-two patients underwent angiography 1 to 127 months (mean interval 33 months) after surgery. Of 73 saphenous vein grafts studied, 62 (85%) were patent. Patency rates for grafts to each coronary vessel were left anterior descending, 26 of 31 (84%); diagonal, 10 of 11 (91%); circumflex, 15 of 18 (83%); and right, 12 of 15 (80%). Two mammary artery grafts were studied and both were patent.
Discussion
Early reports of operations combining either mitral or aortic valve replacement with coronary bypass 1186 grafting have documented high operative mortality. Although early risk has decreased for patients undergoing aortic valve replacement combined with coronary bypass grafting, due in large part to effective intraoperative myocardial protection with cardioplegia,' 1 comparable improvement in operative mortality has not been demonstrated for patients undergoing mitral valve replacement and myocardial revascularization. While the overall operative mortality of 7.3% for the patients in this series is only slightly higher than the 5.9% risk for aortic valve replacement and revascularization at our institution from 1967 to 1981, the recent operative mortality for aortic valve replacement and coronary bypass grafting has declined to 3.4%, whereas the risk for mitral valve replacement and revascularization has remained at 7%. When assessing overall risk for such a heterogeneous group of patients, unfavorable results for small subsets of high-risk patients can make the outlook seem unduly pessimistic for the entire patient subset. DiSesa et al. 7 mortality in previous studies have been age over 60, preoperative symptoms of NYHA functional class IV, and left ventricular ejection fraction less than 55%.7-9
We did not find age, preoperative symptom status, or angiographic left ventricular function to influence early risk. When we examined the extremes of the hemodynamic parameters of left ventricular end-diastolic pressure ('40 mm Hg) and pulmonary capillary wedge pressure (>40 mm Hg), they were associated with decreased survival. Unfortunately, these hemodynamic data were unavailable for enough patients to preclude their inclusion in multivariate testing. Cardiothoracic ratio, perhaps an indirect parameter of myocardial function in patients with mitral valve disease, was a marker of risk. Cardiac rhythm was also influential since patients who were pacemakerdependent or in atrial fibrillation were at increased risk. Previous studies of mitral valve replacement and revascularization have not evaluated preoperative rhythm. Left main stenosis of 70% or more also was associated with a slight increase in risk in our series, as was an elevated serum bilirubin. However, although there was a trend toward increased mortality for patients with ischemic valve disease, we did not find the influence of valve pathology to be significant by either univariate or multivariate testing. Simple strategies that might decrease operative risk for these patients below current levels are not obvious. Reviewing aortic valve replacement and revascularization, we found that almost all operative deaths (25 of 29) were primarily due to cardiac causes.'0 However, in the present series only 11 of 22 deaths were primarily cardiac. The observation that perioperative mortality did not correlate precisely with the occurrence of perioperative myocardial injury may, in part, explain why the use of cardioplegia did not significantly lower operative risk. Noncardiac morbidity had a major impact on operative mortality and advancements in perioperative care may favorably affect early mortality after mitral valve replacement and revascularization.
Studies comparing mortality for isolated mitral valve replacement with that for valve replacement and bypass grafting have shown higher operative mortality rates associated with the combined operation.6-8. 14 However, it appears that the increased perioperative risk is caused primarily by the coronary pathoanatomy, not by the coronary bypass grafting performed to treat that pathology. Two groups have noted that patients undergoing mitral valve replacement and revascularization were at increased risk compared with patients without coronary disease undergoing isolated mitral valve replacement, but that patients with coronary dis-ease who underwent mitral valve replacement without bypass grafting had the highest risk of any of the three subgroups. 8' 16 Data concerning patients with mild or moderate mitral insufficiency who in addition had significant coronary artery disease suggest that valve replacement is not indicated in that setting. Pinson et al. '7 treated 19 patients with moderate ischemic mitral insufficiency with only coronary bypass grafting and documented a 5 year survival of 72%. Isolated coronary bypass grafting in 67 of their patients with mild mitral insufficiency resulted in a 4% operative mortality and 5 year survival of 82%. Geha et al. 9 have made similar observations. These data, the operative risk of combining mitral valve replacement and revascularization, and the risks of late prosthesis-related complications imply that mitral valve replacement in combination with bypass grafting is indicated only for severe valvular dysfunction.
Although patients undergoing conservative mitral valve operations were excluded from this study, mitral valve reconstruction combined with bypass grafting represents another alternative for patients with combined mitral valve and coronary pathology. 18, 19 Valve reconstruction is a more complex operation than valve replacement. On the other hand, some data suggest that left ventricular function after annuloplasty is superior to that after valve replacement. 20 The bulk of currently existing data regarding conservative mitral valve surgery for mitral insufficiency are observations regarding a different patient population than that reviewed here and the effect the more widespread use of reconstructive techniques will have on perioperative risk and late survival is not yet known.
Existing data document that long-term survival after mitral valve replacement is compromised by the presence of significant coronary artery disease and that the adverse effect of coronary disease is not completely ameliorated by bypass grafting.6' 8 Comparison of late survival after mitral valve replacement and revascularization with that for our patients undergoing aortic valve replacement and bypass grafting shows hospital survivors had a similar 2 year survival (85% vs 87%), but beyond that point the mitral group had more late attrition, with 66% and 31 % surviving at 5 and 10 postoperative years, respectively, compared with 80% and 55% for the aortic group." Death from congestive heart failure was more common and sudden death was less common in the mitral group relative to patients undergoing aortic valve replacement and bypass grafting.
Specific factors that have been previously cited as THERAPY AND PREVENTION-CARDIAC SURGERY decreasing late survival of patients undergoing mitral replacement combined with revascularization have been ischemic mitral valve disease, poor left ventricular ejection fraction, and the number of stenotic coronary arteries.7 -9 We did not demonstrate a strong influence of valve pathology on late survival. In the multivariate setting, both rheumatic and ischemic disease were associated with a slightly lower survival when compared with degenerative valve disease. In previous studies, a variety of criteria have been used for the definition of ischemic valve disease. 21 We used very strict criteria for that diagnosis. A relatively small proportion of our patients were classed as having ischemic valve pathology and a larger proportion were considered to have degenerative lesions, a situation one would expect to heighten any adverse effect of ischemic valve pathology. However, even the group of patients with true ischemic mitral valve disease is a heterogeneous one. The long-term outcome in the entire group of patients with ischemic valve disease was enhanced by the excellent longevity among survivors of operation for papillary muscle rupture. Patients with ischemic valve disease but without papillary muscle rupture had dismal late results, which is more consistent with previous data. 8 22 Not surprisingly, left ventricular dysfunction adversely influenced late survival. Some index of preoperative left ventricular function has been found to be a determinant of late survival in most studies of isolated mitral valve replacement, mitral valve replacement with revascularization, and isolated coronary bypass grafting.
In our series the strongest patient-related predictor of late survival was the presence of postoperative inhospital ventricular arrhythmias. Little data exist regarding the influence of ventricular arrhythmias on long-term survival after valve replacement. Our patients were routinely monitored for only the first 48 postoperative hours. We must therefore assume that our detection of arrhythmias was an underestimation, which may have diminished the impact of that descriptor. Studies of patients with aortic valve disease have correlated ventricular arrhythmias with poor left ventricular function.23 In this study, there was no such significant correlation, and the presence of arrhythmias compromised late survival more than poor left ventricular function did.
We did not find any evidence that number of stenotic coronary arteries, hemodynamic valve lesions, or extent and type of preoperative symptoms influenced survival.
The most important correlates of late survival were not patient-related but management-related: the type of prosthesis and use of anticoagulants. Patients with bioprostheses who were not taking warfarin had better survival than other valve-anticoagulation groups did.
We also found this to be true in our review of aortic valve replacement combined with coronary bypass grafting. "l Previous study of patients after mitral valve replacement and coronary bypass grafting has not shown an influence of prosthesis type on late survival. Czer et al.8 used both mechanical and bioprostheses but a comparison showed no difference. However, all of their patients were given anticoagulants regardless of prosthesis type. We also found that in our patients who had bioprostheses but who continued to take warfarin survival was no better than in patients with mechanical prostheses.
Conflicting data exist regarding the comparison of bioprostheses and mechanical prostheses in patients who have undergone isolated mitral replacement. Marshall et al.24 compared patients who received either a tilting-disk prosthesis or a porcine heterograft and found no difference in survival or event-free survival at 3 to 4 postoperative years. Furthermore, only 12 of their 96 patients with porcine valves received anticoagulants. Conversely, Cohn et al.25 found that patients with bioprostheses who were not taking anticoagulants had a better survival rate for 22 months than did patients with disk valves who were taking warfarin.
Examination of event-free survival documented a substantial incidence of late complications, with less than half of hospital survivors living 5 years without experiencing a late event. The definition of an event was broad and included any hospital admission for cardiac-related causes, including the occurrence of congestive heart failure. Prosthesis-anticoagulation group was the major determinant of event-free survival since, again, patients with bioprostheses who did not take anticoagulants had the best outcome. This is a retrospective study and neither selection of prosthesis nor anticoagulation strategy was randomized. However, analysis of the prosthesis-anticoagulation groups showed no significant differences in terms of age, left ventricular function, and presence of ventricular arrhythmia. Patients with rheumatic valve pathology were slightly more likely to have received mechanical valves. Examination of the relationship between preoperative rhythm and anticoagulation strategy showed that patients in atrial fibrillation were more likely to have received anticoagulants than were those in sinus rhythm, consistent with standard prac-tice at many institutions. However, the enhanced survival of the patients not taking anticoagulants was not based on an association with sinus rhythm. Rhythm by itself had no apparent effect on long-term outcome. In fact, avoiding anticoagulants appeared most advantageous for patients with bioprostheses who were in atrial fibrillation; in patients with bioprostheses who were in sinus rhythm there was less of a difference in survival based on whether or not they had taken anticoagulants. Finally, the use of multivariate techniques established that prosthesis-anticoagulation group was more influential than the patient-related variables included in the model.
This study suggests that warfarin may not be indicated for patients with mitral bioprostheses even in the presence of atrial fibrillation. Whether or not this policy is applicable to all subgroups of patients with mitral bioprostheses is unclear and resolution of that question will require study of a larger patient population. Bioprostheses in the mitral position appear to positively influence survival and event-free survival for at least 6 postoperative years, but because of the length of follow-up, conclusions regarding their efficacy beyond that point cannot be made from these data.
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